|Bid||31.60 x 1100|
|Ask||31.63 x 1800|
|Day's Range||31.42 - 32.56|
|52 Week Range||25.25 - 35.46|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||125.28|
|Earnings Date||Feb 18, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.50|
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. The common stock offering was upsized from the previously announced offering size of 19,159,866 shares of common stock. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT." The offerings are expected to close on January 27, 2020, subject to customary closing conditions.
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it intends to make concurrent public offerings of 19,159,866 shares of its common stock and 11,000,000 tangible equity units, with an aggregate stated amount of $550 million for the units. Each tangible equity unit has a stated amount of $50 and is composed of (i) a prepaid stock purchase contract and (ii) a senior amortizing note due February 1, 2023 each issued by Elanco. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT."
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement to divest the U.S. rights to Capstar®, an oral tablet that kills fleas in dogs and cats, to PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication and wellness company, for $95 million in an all-cash deal. The product had 2018 revenue of $28.5 million.
PetIQ, Inc. (“PetIQ” or the “Company”) (PETQ), a leading pet medication and wellness company, and Elanco today announced they have executed a definitive agreement under which PetIQ will acquire Capstar®, the #1 oral over-the-counter (“OTC”) flea treatment product in the United States, from Elanco Animal Health, Inc. (“Elanco”) (ELAN). The $95 million cash transaction has been unanimously approved by PetIQ’s and Elanco’s Board of Directors. PetIQ expects that this acquisition will be immediately accretive to earnings following the closing and thereafter.
Benzinga Pro's Stocks To Watch For Friday Eli Lilly (LLY) - Shares were quiet Friday morning despite news the company will purchase Dermira (DERM) for $18.75/share in cash. Dermira shares were up about ...
Shares of Elanco Animal Health Inc. fell 0.9% in premarket trading Friday after the company provided 2020 profit guidance that was below analyst expectations. The company said it expects net earnings per share of 4 cents to 16 cents in 2020 and adjusted EPS, which excluding non-recurring items, of $1.09 to $1.16. The FactSet EPS consensus is $1.21. Elanco said it expects total revenue of $3.05 billion to $3.11 billion, compared with the FactSet consensus of $3.11 billion. For 2019, Elanco said the expected results are "consistent" with guidance provided in November, when the company said it expects adjusted EPS of $1.04 to $1.08 and total revenue of $3.070 billion to $3.085 billion. Elanco's stock has lost 11.2% over the past 12 months through Thursday, while the S&P 500 has gained 26.1%.
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its initial financial guidance for 2020, including total revenue expectations in the range of $3.05 billion to $3.11 billion, and Core Revenue, which excludes strategic exits, in the range of $3.00 billion to $3.06 billion. Elanco also expects earnings per share (EPS) for 2020 to be in the range of $0.04 to $0.16 on a reported basis and $1.09 to $1.16 on an adjusted basis. These revenue and EPS expectations are for stand-alone Elanco only, including full year revenues for products that may be divested, and do not include any expected revenues from the Bayer animal health business or impact of transactions related to the acquisition, such as potential issuance of additional shares.
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its financial guidance for 2020 on Friday, January 10, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s financial guidance.
Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has signed an agreement to divest Osurnia®, a treatment for otitis externa in dogs, to Dechra Pharmaceuticals PLC (LON: DPH) for $135 million in an all-cash deal.
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET (9:30 a.m. PT).
Elanco Animal Health Incorporated (NYSE: ELAN) has signed an agreement to sell its Victoria, Prince Edward Island (PEI) aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI.
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received a second request for information from the U.S. Federal Trade Commission (FTC) in regards to its previously announced acquisition of Bayer AG’s (ETR: BAYN) animal health business. The request was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the review continues to progress as expected.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Elanco Animal Health Inc. (ELAN) today announced Sara Place, Ph.D., has joined the company as Chief Sustainability Officer, emphasizing the company’s continued commitment to make an impact on societal challenges by improving the health of animals. Place will join Elanco’s team of scientific experts: Chief Medical Officer Shabbir Simjee and Chief Animal Welfare Officer Michelle Calvo-Lorenzo. The group helps Elanco and its customers identify new opportunities to continue improving sustainable business practices, improve the well-being of animals and people, and reduce the environmental footprint of protein production by keeping food animals healthier.
Wall Street has high hopes for the alternative-meat industry. If the world does end up eating less animal-based protein in the future, other industries—besides just meat producers—will be affected.
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
While Elanco Animal Health Inc’s (NYSE: ELAN ) current valuation reflects the ongoing investor concerns, the focus is now likely to shift to the positives related to the Bayer transaction, prospects of ...
Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.
GREENFIELD, Ind.-- -- Earnings per share was $0.03 , or $0.30 for the third quarter 2019, including a benefit of $0.02 from a tax item Gross margin improved to 53.3 percent of revenue , an improvement of 190 basis points and 210 basis points for the third quarter 2019 Total Revenue in the third quarter of 2019 increased 1 percent to $771.3 million; Total and Core Revenue grew 2 percent and 4 percent, ...